Our Solutions Portfolio

Vaccines have been pivotal in the fight against infectious diseases, significantly reducing global morbidity and mortality. Over decades, vaccines have eradicated diseases like smallpox and drastically lowered the incidence of polio and measles. In addition to childhood immunizations, adult vaccination is emerging as a critical segment of the vaccine market, addressing conditions such as influenza, shingles, human papillomavirus (HPV), and pneumococcal disease. 

The global vaccine market is projected to grow at a compound annual growth rate (CAGR) of approximately 6.6%-9%over the next decade, with adult vaccines playing a pivotal role in this expansion (Li et al., 2021). By 2033, adult vaccines are expected to contribute 35%-40% of total vaccine market revenues, up from 25% in 2022.

Key drivers of this growth include:

1. Rising Burden of Adult Diseases: Aging populations in high-income countries have heightened the need for vaccines targeting shingles, influenza, and pneumococcal infections (Hurley et al., 2014).
2. Technological Advancements: Innovations like mRNA vaccine platforms have enabled faster development of adult vaccines, including those for respiratory syncytial virus (RSV) and COVID-19 (Wang et al., 2020).
3. Global Awareness Campaigns: Efforts to boost adult vaccination rates have emphasized the prevention of vaccine-preventable diseases, particularly in vulnerable populations.

• Eastern Europe & Eurasia:
  
  • Prevalence: HPV prevalence in women with normal cytology is 12.6%. HPV16 and HPV18 account for 87.5% of cervical cancer cases (Poljak et al., 2013).
  • Coverage: Vaccination coverage is under 50% in most areas, limited by high costs and vaccine hesitancy (Rogovskaya et al., 2013).

• LATAM:
  
  • Prevalence: HPV prevalence is 16.1%, with cervical cancer rates among the highest globally (Bruni et al., 2010).
  • Coverage: Brazil and Argentina report ~75% vaccination coverage in urban areas, but rural access remains limited.

• SEA:
  
  • Prevalence: HPV prevalence ranges from 9%-18%, with HPV16 and HPV18 as the leading causes of cervical cancer (Farahmand et al., 2019).
  • Coverage: Coverage is below 40% in rural areas due to logistical challenges and cost constraints.

• MEA:
  
  • Prevalence: HPV prevalence is 9.3%. Types HPV16 and HPV18 dominate cervical cancer cases (Farahmandet al., 2019).
  • Coverage: Public mistrust and affordability challenges keep vaccination rates below 20%.

• Eastern Europe & Eurasia:
  
  • Burden: IPD incidence before PCV introduction was 44.4/100,000 in children under two years (Isaacman etal., 2010).
  • Coverage: Urban centers report >85% uptake, with rural areas lagging behind.

• LATAM:
  
  • Burden: Streptococcus pneumoniae remains a significant cause of childhood deaths. Immunization programs in Brazil and Argentina have expanded PCV coverage, though rural gaps persist (Moreira et al., 2016).

• SEA:
  
  • Burden: Pneumonia remains a leading cause of under-five mortality. PCV coverage is below 70% in underserved regions (Isaacman et al., 2010).

• MEA:
  
  • Burden: Streptococcus pneumoniae causes 15% of under-five mortality. PCV adoption is a priority but coverage is below 50% in many low-income areas.

• Eastern Europe & Eurasia:
  
  • Coverage: DTP3 vaccination exceeds 90% in urban areas but drops to 70%-80% in rural regions (McCormick & Czachor, 2013).

• LATAM:
  
  • Progress: Brazil has achieved 97% DTP coverage, significantly reducing pertussis cases (McCormick & Czachor, 2013).

• SEA:
  
  • Challenges: Coverage averages 80%-85%, but booster coverage for older children remains low.

• MEA:
  
  • Gaps: Booster doses are inconsistently administered, affecting long-term immunity.

• Eastern Europe & Eurasia:
  
  • Burden: Shingles incidence is rising due to aging populations, with over 1 in 3 adults aged 60+ affected. Vaccine uptake is low due to lack of awareness.
  • Coverage: Few national programs offer subsidized shingles vaccines.

• LATAM:
  
  • Burden: Increasing incidence among older adults, especially those with weakened immune systems. Coverage remains low due to cost barriers.

• SEA:
  
  • Burden: Rising incidence in urban centers, though shingles vaccines are not widely included in immunization programs.

• MEA:
  
  • Burden: Shingles awareness is low, and vaccination rates are negligible due to high costs and lack of public health prioritization.

• Respiratory Syncytial Virus (RSV):
  
  • MEA & SEA: RSV remains a leading cause of severe respiratory illness in infants. Maternal RSV vaccines are in early stages of implementation, targeting pregnant women in high-risk regions.

• Tetanus:
  
  • LATAM, SEA, MEA: Maternal tetanus vaccination campaigns have drastically reduced neonatal tetanus rates by up to 80%.

1. Affordability: HPV and shingles vaccines are particularly expensive, limiting coverage in low-income regions.
2. Awareness: Shingles and maternal RSV vaccines suffer from low awareness across all regions.
3. Infrastructure: SEA and MEA face significant logistical and cold chain challenges.
4. Mistrust: Vaccine hesitancy, especially for HPV and new vaccines, limits uptake in Eastern Europe and MEA.
5. Policy: Subsidies and expanded immunization programs are crucial for improving access to essential vaccines.